IVIG in bone marrow transplantation


Journal Article

The principal causes of allogeneic transplant-related mortality are graft- versus-host disease (GVHD), interstitial pneumonia, and cytomegalovirus (CMV) infection. In bone marrow-transplant recipients, intravenous immunoglobulin (IVIG) has shown the ability to reduce the incidence of symptomatic CMV infection and interstitial pneumonia. Reductions in acute GVHD, bacteremia, septicemia, and local infection have been observed in IVIG recipients in the first 100 days post-transplant. Reduction in transplant-related mortality has also been observed, especially among adult patients receiving allogeneic marrow grafts.

Duke Authors

Cited Authors

  • Sullivan, K

Published Date

  • January 1, 1996

Published In

Volume / Issue

  • 21 / 4 SUPPL.

International Standard Serial Number (ISSN)

  • 1052-1372

Citation Source

  • Scopus